NO943451L - Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer - Google Patents

Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer

Info

Publication number: NO943451L
Authority: NO; Norway
Prior art keywords: pct; treatment; mannose; phosphates; fibrotic diseases
Prior art date: 1992-03-17

Application number

NO943451A

Other languages

English (en)

Other versions

NO306808B1 (no

NO943451D0 (no

Inventor

Mark William James Ferguson

Original Assignee

British Tech Group

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-17

Filing date

1994-09-16

Publication date

1994-09-16

1994-09-16 Application filed by British Tech Group filed Critical British Tech Group

1994-09-16 Publication of NO943451L publication Critical patent/NO943451L/no

1994-09-16 Publication of NO943451D0 publication Critical patent/NO943451D0/no

1999-12-27 Publication of NO306808B1 publication Critical patent/NO306808B1/no

Links

229910019142 PO4 Inorganic materials 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000003176 fibrotic effect Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
-1 mannose phosphates Chemical class 0.000 title 1
235000021317 phosphate Nutrition 0.000 title 1
NDVRKEKNSBMTAX-MVNLRXSJSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O NDVRKEKNSBMTAX-MVNLRXSJSA-N 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000036573 scar formation Effects 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)

NO943451A 1992-03-17 1994-09-16 Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer NO306808B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929205800A GB9205800D0 (en)	1992-03-17	1992-03-17	Treatment of fibrotic disorders
PCT/GB1993/000541 WO1993018777A1 (en)	1992-03-17	1993-03-16	Use of mannose phosphates for the treatment of fibrotic disorders

Publications (3)

Publication Number	Publication Date
NO943451L true NO943451L (no)	1994-09-16
NO943451D0 NO943451D0 (no)	1994-09-16
NO306808B1 NO306808B1 (no)	1999-12-27

Family

ID=10712310

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO943451A NO306808B1 (no)	1992-03-17	1994-09-16	Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer

Country Status (18)

Country	Link
US (1)	US5520926A (no)
EP (1)	EP0728006B1 (no)
JP (1)	JP3930556B2 (no)
AT (1)	ATE196847T1 (no)
AU (1)	AU667887B2 (no)
CA (1)	CA2130805C (no)
DE (1)	DE69329559T2 (no)
DK (1)	DK0728006T3 (no)
ES (1)	ES2151903T3 (no)
GB (2)	GB9205800D0 (no)
GR (1)	GR3035117T3 (no)
IL (1)	IL105079A (no)
NO (1)	NO306808B1 (no)
NZ (1)	NZ249915A (no)
PT (1)	PT728006E (no)
SG (1)	SG49899A1 (no)
WO (1)	WO1993018777A1 (no)
ZA (1)	ZA931869B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing
SE9403137D0 (sv) *	1994-09-20	1994-09-20	Perstorp Ab	Derivatives of carbohydrates and compositions containing them
GB9516012D0 (en) *	1995-08-04	1995-10-04	Univ Manchester	Pharmaceutical composition
US6566339B1 (en)	1995-08-04	2003-05-20	Renovo Limited	Pharmaceutical composition
GB2306481A (en) *	1995-10-21	1997-05-07	Univ Manchester	Pharmaceutical comprising a stimulator of activin and/or inhibin
US6093388A (en) *	1996-08-12	2000-07-25	Btg International Limited	Mannose-6-phosphate composition and its use in treating fibrotic disorders
GB9616896D0 (en) *	1996-08-12	1996-09-25	British Tech Group	Pharmaceutical compositions
DE19758059C2 (de) *	1997-12-29	2001-10-04	Thorsten Marquardt	Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie
WO2002030432A1 (en) *	2000-06-23	2002-04-18	Cambridgemed, Inc	Agent for reduction of scar formation by using wound alkalinization
WO2002043731A2 (en) *	2000-11-30	2002-06-06	University Of Florida	Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US20030031689A1 (en) *	2001-08-09	2003-02-13	Thomas Mammone	Method of skin exfoliation
US6822033B2 (en)	2001-11-19	2004-11-23	United States Gypsum Company	Compositions and methods for treating set gypsum
EP1478354A4 (en) *	2002-01-22	2008-09-24	Genzyme Corp	USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
WO2003094937A1 (en) *	2002-05-09	2003-11-20	Medigenes	A pharmaceutical composition for treatment of wounds containing blood plasma or serum
GB0217136D0 (en)	2002-07-24	2002-09-04	Renovo Ltd	Wound healing & treatment of fibrosis
KR100492913B1 (ko) *	2002-08-23	2005-06-03	주식회사 태평양	피부 감작 및 자극을 완화하는 피부 외용제 조성물
US20050136126A1 (en) *	2003-03-17	2005-06-23	Cambridgemed, Inc.	Agent for reduction of scar formation by using wound alkalinization
JP4634027B2 (ja) *	2003-05-16	2011-02-16	花王株式会社	ビタミンｄ様活性代替用剤
US7276486B2 (en) *	2004-03-15	2007-10-02	Kimberly-Clark Worldwide, Inc.	Compositions for vaginal treatment
CA2561686C (en)	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
JP5481028B2 (ja) *	2004-10-13	2014-04-23	ザオハイオステートユニバーシティーリサーチファウンデーション	ウイルス関連リンパ増殖性障害を処置または予防するための方法
US20070048391A1 (en) *	2005-08-23	2007-03-01	Cambridgemed, Inc.	Composition for reduction of scar formation on wound scar
US7323184B2 (en) *	2005-08-22	2008-01-29	Healagenics, Inc.	Compositions and methods for the treatment of wounds and the reduction of scar formation
WO2007050793A2 (en)	2005-10-25	2007-05-03	The Johns Hopkins University	Methods and compositions for the treatment of marfan syndrome and associated disorders
EP2230252A1 (en)	2006-03-13	2010-09-22	The Johns Hopkins University	Augmentation of endothelial thromboresistance
EP2918288B1 (en)	2006-10-03	2017-08-16	Genzyme Corporation	Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US8070895B2 (en)	2007-02-12	2011-12-06	United States Gypsum Company	Water resistant cementitious article and method for preparing same
US8329308B2 (en)	2009-03-31	2012-12-11	United States Gypsum Company	Cementitious article and method for preparing the same
GB0910078D0 (en) *	2009-06-11	2009-07-22	Renovo Ltd	Uses of mannose-6-phosphate
GB0916334D0 (en) *	2009-09-17	2009-10-28	Renovo Ltd	Inhibition of tendon adhesions
GB0916333D0 (en)	2009-09-17	2009-10-28	Renovo Ltd	Improvement of tendon repair
TR201816180T4 (tr)	2010-03-12	2018-11-21	Genzyme Corp	Meme kanserini tedavi etmek için kombinasyonlu tedavi.
WO2012087434A2 (en) *	2010-11-05	2012-06-28	Healthypharma, Llc	Use of phosphoric acid
CA2823154A1 (en)	2010-12-27	2012-07-05	Lsip, Llc	Ips cells and method for generating same
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt)	2011-10-26	2017-04-25	Seattle Children's Res Inst	cisteamina no tratamento da doença fibrótica
EP2799537B1 (en)	2011-12-28	2021-09-22	Kyoto Prefectural Public University Corporation	Normalization of culture of corneal endothelial cells
WO2015064768A1 (ja)	2013-10-31	2015-05-07	京都府公立大学法人	角膜内皮の小胞体細胞死関連疾患治療薬
US10882903B2 (en)	2015-05-18	2021-01-05	Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
CA3245007A1 (en) *	2022-03-08	2023-09-14	University Of Mississippi Medical Center	ARTICLES AND PROCESSES FOR IMPROVED BIOLOGICAL TISSUE HEALING
CN115260256A (zh) *	2022-07-22	2022-11-01	河南中医药大学	一种甘露糖磷酸化衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE756953A (fr) *	1969-10-02	1971-04-01	Merck & Co Inc	Potentialisation d'antibiotiques
JPS5631156B2 (no) *	1973-09-25	1981-07-20
IT1170618B (it) *	1981-01-13	1987-06-03	Foscama Biomed Chim Farma	Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati
US4703040A (en) *	1985-04-03	1987-10-27	Markov Angel K	Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
ATE78166T1 (de) *	1985-10-22	1992-08-15	Silvetti Anthony N	Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
US4889844A (en) *	1985-10-22	1989-12-26	Silvetti Sr Anthony N	Fructose containing wound healing preparation
AU607690B2 (en) *	1985-12-24	1991-03-14	Marion Laboratories, Inc.	Use of synthetic sulfated saccharides to enhance wound healing
JPS62243675A (ja) *	1986-04-15	1987-10-24	Kao Corp	ｐＨ緩衝法
ATE139699T1 (de) *	1988-08-19	1996-07-15	Univ Australian	Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
GB8917414D0 (en) *	1989-07-29	1989-09-13	Translift Material Handling	Narrow aisle lift truck
EP0775742A3 (en) *	1989-09-29	1998-01-14	La Jolla Cancer Research Foundation	Inhibiting transforming growth factor beta to prevent accumulation of axtracellular matrix
SE8904354D0 (sv) *	1989-12-21	1989-12-21	Matti Siren	A pharmaceutical composition
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing
JPH0558868A (ja) *	1991-08-27	1993-03-09	Kao Corp	親水性紫外線吸収剤及びこれを含有する化粧料
WO1993019783A1 (en) *	1992-04-01	1993-10-14	The Whittier Institute For Diabetes And Endocrinology	Methods of inhibiting or enhancing scar formation in the cns
JPH09155319A (ja) *	1995-12-13	1997-06-17	Takeo Tsutsui	重金属含有焼却灰等、シュレッダーダストの無公害化処理方法および再利用材の製造方法

1992
- 1992-03-17 GB GB929205800A patent/GB9205800D0/en active Pending
1993
- 1993-03-16 ES ES93906680T patent/ES2151903T3/es not_active Expired - Lifetime
- 1993-03-16 AT AT93906680T patent/ATE196847T1/de active
- 1993-03-16 EP EP93906680A patent/EP0728006B1/en not_active Expired - Lifetime
- 1993-03-16 ZA ZA931869A patent/ZA931869B/xx unknown
- 1993-03-16 AU AU37590/93A patent/AU667887B2/en not_active Expired
- 1993-03-16 DK DK93906680T patent/DK0728006T3/da active
- 1993-03-16 IL IL105079A patent/IL105079A/en not_active IP Right Cessation
- 1993-03-16 WO PCT/GB1993/000541 patent/WO1993018777A1/en not_active Ceased
- 1993-03-16 JP JP51635793A patent/JP3930556B2/ja not_active Expired - Lifetime
- 1993-03-16 GB GB9305344A patent/GB2265310B/en not_active Expired - Lifetime
- 1993-03-16 CA CA002130805A patent/CA2130805C/en not_active Expired - Lifetime
- 1993-03-16 US US08/290,939 patent/US5520926A/en not_active Expired - Lifetime
- 1993-03-16 DE DE69329559T patent/DE69329559T2/de not_active Expired - Lifetime
- 1993-03-16 PT PT93906680T patent/PT728006E/pt unknown
- 1993-03-16 NZ NZ249915A patent/NZ249915A/en not_active IP Right Cessation
- 1993-03-16 SG SG1996008660A patent/SG49899A1/en unknown
1994
- 1994-09-16 NO NO943451A patent/NO306808B1/no not_active IP Right Cessation
2000
- 2000-12-19 GR GR20000402805T patent/GR3035117T3/el unknown

Also Published As

Publication number	Publication date
DE69329559D1 (de)	2000-11-16
US5520926A (en)	1996-05-28
JP3930556B2 (ja)	2007-06-13
GB2265310B (en)	1996-09-25
NO306808B1 (no)	1999-12-27
ES2151903T3 (es)	2001-01-16
CA2130805A1 (en)	1993-09-30
IL105079A (en)	1998-06-15
DE69329559T2 (de)	2001-05-31
AU3759093A (en)	1993-10-21
NZ249915A (en)	1996-08-27
WO1993018777A1 (en)	1993-09-30
ATE196847T1 (de)	2000-10-15
DK0728006T3 (da)	2000-10-30
GR3035117T3 (en)	2001-03-30
GB9305344D0 (en)	1993-05-05
IL105079A0 (en)	1993-07-08
EP0728006A1 (en)	1996-08-28
PT728006E (pt)	2001-04-30
EP0728006B1 (en)	2000-10-11
AU667887B2 (en)	1996-04-18
JPH07504909A (ja)	1995-06-01
GB2265310A (en)	1993-09-29
ZA931869B (en)	1994-09-16
CA2130805C (en)	2003-06-24
NO943451D0 (no)	1994-09-16
GB9205800D0 (en)	1992-04-29
SG49899A1 (en)	1998-06-15

Legal Events

Date	Code	Title	Description
2013-04-15	MK1K	Patent expired

Publication	Publication Date	Title
NO943451D0 (no)	1994-09-16	Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer
NO307027B1 (no)	2000-01-31	Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
FI970101A0 (fi)	1997-01-10	Uusi farmaseuttinen valmiste kivun hallintaan
KR960701051A (ko)	1996-02-24	이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
AU5144396A (en)	1996-10-02	Trisubstituted phenyl derivatives
ATE217197T1 (de)	2002-05-15	Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
FI964332A0 (fi)	1996-10-28	Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DE69424777D1 (de)	2000-07-06	3,4-diarylchromane zur behandlung von dermatitis
EP0746313A4 (en)	1994-10-20	METHOD FOR TREATING SMALL Mouth Ulcers
EP0744176A3 (en)	2002-05-15	Methods for inhibiting bone loss
DK1291018T3 (da)	2005-09-12	Phosphonatananaloger til mannose-6phosphat og deres anvendelse i behandlingen af sår og fibrotiske lidelser
NZ299257A (en)	2000-08-25	Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
AU1278600A (en)	2000-06-13	Novel therapeutic application of nicergoline
DE69307702D1 (de)	1997-03-06	Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE254919T1 (de)	2003-12-15	Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
DE69832796D1 (de)	2006-01-19	Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
UA10259A (uk)	1996-12-25	Протинабряковий лікарський препарат "нейрополіосм"
ATE99933T1 (de)	1994-01-15	Mittel zur behandlung von nierenbeschwerden.